AACR charts a broad research agenda for cancer prevention
The AACR white paper frames cancer prevention as a fast-moving field rather than a static public health program. In the view laid out by the summit organizers, recent advances have already changed how prevention science is studied, funded, and translated into practice. The document centers on five research priorities: the Precancer Atlas, cancer interception, the obesity-cancer link, implementation science, and cancer disparities.
The scope is wide, but the message is direct. Prevention is no longer limited to screening, vaccination, or behavior change alone. The field now includes molecular characterization of precancerous tissue, early intervention against emerging malignant clones, and strategies to move proven interventions into routine care and community settings.
Precancer biology moves to the center of prevention strategy
A major theme in the white paper is the need to define the biology of disease before invasive cancer develops. The proposed Precancer Atlas reflects that goal. By mapping the cellular and molecular features of precursor lesions, investigators can identify the earliest disruptions that precede overt malignancy and, in principle, target them before clinical cancer emerges.
The report points to several examples that show how this approach is already influencing the field. Cell-free epigenetic marks can identify an incipient neoplastic site, offering a route toward earlier localization of disease. In pancreatic precursors, microbiota-driven IL-17 can induce stemness and transformation, creating another biologically grounded target for intervention. These kinds of observations matter because they move prevention upstream, toward the moments when tissue state is still reversible or at least more tractable than established cancer.
A single lesion is no longer viewed in isolation.
Cancer interception expands prevention beyond risk reduction
The white paper gives substantial attention to cancer interception, a concept that reaches beyond classic prevention and into active interruption of biological progression. Several repurposing opportunities are already in view, including agents targeting immune and stem-cell signals such as IL-1β, PD-1, and RANK-L. The rationale is straightforward: if immune signaling, inflammatory tone, or stem-like behavior helps drive neoplastic evolution, then modifying those pathways may interrupt disease before it becomes invasive.
This line of thinking is reflected in other advances cited in the document. Practice-changing genomic subclasses in myeloproliferative neoplasia have refined how inherited and acquired variants are understood, including a germline variant tightly linked to the JAK2 V617F haplotype. Universal germline genetic testing for pancreatic cancer is also presented as part of the shifting prevention framework, reinforcing the idea that inherited susceptibility can guide earlier and more precise action.
Cancer interception is not just a slogan here; it is a research program that links mechanism to intervention.
Obesity, inflammation, and prevention science converge
The summit also placed obesity squarely within the prevention agenda. The white paper describes obesity as a global epidemic of chronic low-grade inflammation, a biologic state with consequences that extend across multiple cancer types. The decision to hold an obesity special conference signals the intention to connect epidemiology with molecular biology rather than treating body weight as a purely behavioral or demographic variable.
That framing has practical implications. If obesity contributes to carcinogenesis through inflammatory signaling, metabolic disruption, and altered tissue microenvironments, then prevention research has to address those pathways directly. The white paper presents this as part of a broader shift toward linking population-level patterns with tissue-level mechanisms. For cancer prevention, that bridge is essential, because it helps explain why a common exposure can shape risk across diverse organs and patient groups.
Implementation science determines whether discoveries reach patients
The document makes clear that discovery alone is not enough. Implementation science is one of the five priority areas because prevention only matters if proven measures are actually used. The AACR’s work with national and global partners reflects that reality, especially in the area of HPV vaccination. Co-leading concerted national implementation efforts in HPV vaccination places prevention into the setting where uptake, access, and adherence determine population benefit.
This practical orientation extends to broader public health policy. The AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, helping to build new global collaborative efforts in cancer control. The white paper presents this as a structural move, not just a scientific one. Prevention research needs coordinated systems, funding pathways, and public-facing strategies if it is going to alter disease burden at scale.
Cancer disparities remain a central scientific and public health problem
Cancer disparities occupy a full place in the roadmap, not a peripheral one. The white paper calls for the future elimination of cancer disparities by integrating new science tools, discoveries, and perspectives into community-engaged research. That includes targeted countermeasures against e-cigarette advertising that exploits children, Hispanics, and Blacks.
The focus on disparities is consistent with the broader prevention agenda because risk does not distribute evenly, and access to prevention does not either. Community engagement matters when interventions must fit lived realities rather than abstract trial conditions. In that sense, the white paper treats disparities research as both a scientific challenge and a public health obligation.
New funding initiatives signal a broader shift in prevention research
Following the summit, two funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot and the AACR-Stand Up To Cancer Cancer Interception initiative. These efforts are presented as tangible outcomes of the summit’s priorities, translating conceptual agreement into research support and programmatic momentum.
The white paper also situates the field within a larger ecosystem of innovation, from NCI-funded built-environment studies to AACR Team Science Awarded projects on Asian cancer genomes informing global primary prevention policies. The underlying message is that cancer prevention now spans environments, genomes, immunity, microbiota, and community behavior. The science is broader, the tools are more specific, and the policy stakes are higher.
The remaining challenge is coordination: turning those separate advances into prevention strategies that can be validated, implemented, and sustained across different populations and cancer types.